Myasthenie und myasthene Syndrome: Was gibt es Neues?

Lernziele

Kenntnisse über

• anti-MuSK- und anti-LRP4-Antikörper-positive Myasthenia gravis

• neue Entwicklungen in der Therapie der Myasthenia gravis

• Diagnose und Therapie des Lambert-Eaton-Syndroms

• Neuromyotonie

• angeborene Störungen der neuromuskulären Signalübertragung

• Literatur

• 1 Köhler W, Sieb JP. Myasthenia gravis. 4.. Aufl. Bremen: UNI-MED; 2012
• 2 Sieb JP. Repetitive Nervenstimulation. Das Neurophysiologie-Labor 2012; 34: 57-67
• 3 Jacob S, Viegas S, Leite MI et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis clustered AChR antibodies in myasthenia gravis. Arch Neurol 2012; 1-8
• 4 Zhang B, Tzartos JS, Belimezi M et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol 2012; 69: 445-451
• 5 Pevzner A, Schoser B, Peters K et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis. J Neurol 2012; 259: 427-435
• 6 Farrugia ME, Robson MD, Clover L et al. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis. Brain 2006; 129: 1481-1492
• 7 Behin A, Mayer M, Kassis-Makhoul B et al. Severe neonatal myasthenia due to maternal anti-MuSK antibodies. Neuromuscul Disord 2008; 18: 443-446
• 8 Poulas K, Koutsouraki E, Kordas G et al. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol 2012; ePub vorab: S0165-5728(12)00165-8 [pii], Doi:
• 9 Gomez AM, Van Den Broeck J, Vrolix K et al. Antibody effector mechanisms in myasthenia gravis-pathogenesis at the neuromuscular junction. Autoimmunity 2010; 43: 353-370
• 10 Cole RN, Reddel SW, Gervasio OL et al. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol 2008; 63: 782-789
• 11 Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010; 23: 530-535
• 12 Pasnoor M, Wolfe GI, Nations S et al. Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve 2010; 41: 370-374
• 13 Niks EH, van Leeuwen Y, Leite MI et al. Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol 2008; 195: 151-156
• 14 Lauriola L, Ranelletti F, Maggiano N et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005; 64: 536-538
• 15 Diaz-Manera J, Martinez-Hernandez E, Querol L et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012; 78: 189-193
• 16 Marouf W, Sieb JP. Myasthenia gravis und myasthene Syndrome. Z Rheumatol 2009; 68: 465-470
• 17 Leite MI, Coutinho E, Lana-Peixoto M et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients. Neurology 2012; 78: 1601-1607
• 18 Kister I, Gulati S, Boz C et al. Neuromyelitis optica in patients with myasthenia gravis who underwent thymectomy. Arch Neurol 2006; 63: 851-856
• 19 Aarli JA. Herzmyasthenie: myasthenia of the heart. Arch Neurol 2009; 66: 1322-1323
• 20 Suzuki S, Utsugisawa K, Yoshikawa H et al. Autoimmune targets of heart and skeletal muscles in myasthenia gravis. Arch Neurol 2009; 66: 1334-1338
• 21 Romi F, Suzuki S, Suzuki N et al. Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis. J Neurol 2012; 259: 1312-1316
• 22 Nagane Y, Suzuki S, Suzuki N et al. Early aggressive treatment strategy against myasthenia gravis. Eur Neurol 2011; 65: 16-22
• 23 Wagner S, Janzen RW, Mohs C et al. Langzeitbehandlung der therapierefraktären Myasthenia gravis mittels Immunadsorption. Dtsch Med Wochenschr 2008; 133: 2377-2382
• 24 Sanders DB, Hart IK, Mantegazza R et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 2008; 71: 400-406
• 25 The Muscle Study Group. A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 2008; 71: 394-399
• 26 Hehir MK, Burns TM, Alpers J et al. Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients. Muscle Nerve 2010; 41: 593-598
• 27 Yoshikawa H, Kiuchi T, Saida T et al. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J Neurol Neurosurg Psychiatry 2011; 82: 970-977
• 28 Heckmann JM, Rawoot A, Bateman K et al. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol 2011; 11: 97
• 29 Pellkofer HL, Armbruster L, Linke R et al. Managing non-paraneoplastic Lambert-Eaton myasthenic syndrome: clinical characteristics in 25 German patients. J Neuroimmunol 2009; 217: 90-94
• 30 Sieb JP, Veauthier C. Lambert-Eaton-Syndrom – Aktuelles zu Diagnose und Therapie. Klin Neurophysiol 2008; 39: 208-218
• 31 de Buys Roessingh AS, Loriot MH, Wiesenauer C et al. Lambert-Eaton myasthenic syndrome revealing an abdominal neuroblastoma. J Pediatr Surg 2009; 44: E5-E7
• 32 Titulaer MJ, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci 2008; 1132: 129-134
• 33 Harms L, Sieb JP, Williams AE et al. Long-term disease history, clinical symptoms, health status and healthcare utilization in patients suffering from Lambert Eaton myasthenic syndroms: results of a patient interview survey in Germany. Journal of Medical Economics 2012; 15: 1-10
• 34 Hatanaka Y, Oh SJ. Ten-second exercise is superior to 30-second exercise for post-exercise facilitation in diagnosing Lambert-Eaton myasthenic syndrome. Muscle Nerve 2008; 37: 572-575
• 35 Oh SJ, Kurokawa K, Claussen GC et al. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 2005; 32: 515-520
• 36 Baslo MB, Deymeer F, Serdaroglu P et al. Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis. Neuromuscul Disord 2006; 16: 454-458
• 37 Oh SJ, Hatanaka Y, Claussen GC et al. Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 2007; 35: 178-183
• 38 Titulaer MJ, Soffietti R, Dalmau J et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 2011; 18: 19-e3
• 39 Titulaer MJ, Klooster R, Potman M et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol 2009; 27: 4260-4267
• 40 Keogh M, Sedehizadeh S, Maddison P. Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2011; 2 CD003279
• 41 Quartel A, Turbeville S, Lounsbury D. Current therapy for Lambert-Eaton myasthenic syndrome: development of 3,4-diaminopyridine phosphate salt as first-line symptomatic treatment. Curr Med Res Opin 2010; 26: 1363-1375
• 42 Skeie GO, Apostolski S, Evoli A et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17: 893-902
• 43 Pellkofer HL, Voltz R, Kümpfel T. Favorable response to rituximab in a patient with anti-VGCC-positive Lambert-Eaton myasthenic syndrome and cerebellar dysfunction. Muscle Nerve 2009; 40: 305-308
• 44 Chalk CH, Murray NM, Newsom-Davis J et al. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990; 40: 1552-1556
• 45 Maddison P. Neuromyotonia. Clin Neurophysiol 2006; 117: 2118-2127
• 46 Lancaster E, Huijbers MG, Bar V et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011; 69: 303-311
• 47 Irani SR, Alexander S, Waters P et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain 2010; 133: 2734-2748
• 48 Müller JS, Herczegfalvi A, Vilchez JJ et al. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes. Brain 2007; 130: 1497-1506
• 49 Senderek J, Muller JS, Dusl M et al. Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect. Am J Hum Genet 2011; 88: 162-172
• 50 Belaya K, Finlayson S, Slater CR et al. Mutations in DPAGT1 cause a limb-girdle congenital myasthenic syndrome with tubular aggregates. Am J Hum Genet 2012; 91: 193-201
• 51 Liewluck T, Selcen D, Engel AG. Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia. Muscle Nerve 2011; 44: 789-794